This hypothesis was derived from the early responses to atRA that were seen in patients with APL before the mechanism of the RARA-PML fusion oncogene was understood, but this hypothesis has since been disproven by clinical data from most cancer types.6 This evidence concerns the gene RARA and acute promyelocytic leukemia.